Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its portfolio company Probiodrug AG released encouraging results from its clinical trial in early Alzheimer’s disease patients. Treatment with Probiodrug’s lead compound PQ912 resulted in significant improvement of working memory and EEG parameter in patients receiving PQ912 as part of the SAPHIR phase 2 a clinical trial.
LSP financed and actively supported Probiodrug since 2009, when LSP co-led the company’s Series B financing round. Since then, the company has transformed from an early stage research and development company into a clinical-stage biotech company, focused on the development of highly innovative Alzheimer’s Disease (AD) treatment to provide a better life for AD patients. PQ912 is a small molecule targeting toxic puroglutamate-Abeta (pGlu-Abeta) by inhibition of the enzyme producing pGlu-Abeta and by clearing existing pGlu-Abeta from the brain. Current estimates are that about 10% of all people aged over 65 years suffer from dementia and disease modifying drugs are desperately needed.
The Probiodrug investment further validates LSP’s long-term approach of identifying break-through technologies, building companies around them and playing an active role all along. Jörg Neermann has represented LSP on the company’s Board and has worked closely with management and other Board members to develop Probiodrug into a successful clinical stage biotech company.
A link to the company's press release can be found at here.
About LSP
LSP is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, LSP’s management has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors.
For more information, please visit www.lspvc.com.
Contact:
Dr Jörg Neermann
Partner LSP
+49 (0)89 330 666 0
« back to overview